Literature DB >> 2566922

Carbostyril-based beta-adrenergic agonists: evidence for long lasting or apparent irreversible receptor binding and activation of adenylate cyclase activity in vitro.

K M Standifer1, J Pitha, S P Baker.   

Abstract

The interaction of the carbostyril derivatives 5-[2-[[1-(4-aminophenyl)-2-methyl-prop-2-yl]amino]-1-hydroxyethyl]- 8-hydroxycarbostyril (carbo-amine) and 5-[2-[[3-[4-(bromoacetamido)phenyl]-2-methylprop-2-yl]amino]-1- hydroxyethyl]-8-hydroxycarbostyril (carbo-Br) with the rat reticulocyte beta-adrenoreceptor system has been partially characterized. In the absence of a guanine nucleotide, the concentration of carbo-amine, carbo-Br and (-)isoprenaline that inhibited (-)-[125I]iodocyanopindolol ([125I]CYP) binding by 50% (IC50) was 5.9 +/- 0.2, 3.3 +/- 0.3 and 49 +/- 3 nM, respectively. In the presence of a guanine nucleotide, the IC50 values were carbo-amine, 21 +/- 0.6 nM; carbo-Br, 7.6 +/- 0.3 nM and (-)isoprenaline, 813 +/- 66 nM. Preincubation of membranes with either of the carbostyril congeners followed by washing reduced specific [125I]CYP binding capacity without changing the KD value for the remaining receptors. The beta-antagonist nadolol largely prevented the receptor reduction induced by the carbostyril compounds. Incubation of membranes for 18 h at 25 degrees C resulted in an 11% recovery of the carbo-amine-induced receptor loss and no recovery of the receptors lost by preincubation with carbo-Br. However, the carbo-amine induced receptor loss could be largely reversed (80%) by membrane heating at 45 degrees C whereas little reversal (less than 10%) was observed with the carbo-Br pretreated membranes. The concentration of carbo-amine, carbo-Br and (-)isoprenaline that stimulated half-maximal cAMP formation in reticulocyte membranes was 17.8 +/- 3.1, 8.2 +/- 2.1 and 241 +/- 17 nM, respectively, and all 3 agonists produced the same maximal response. Initial cAMP formation stimulated by the carbostyril derivatives and (-)isoprenaline was blocked by concurrent addition of propranolol after 7 min of incubation with either of the two carbostyril derivatives did not affect further cAMP production whereas with (-)isoprenaline further cAMP production was blocked.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566922     DOI: 10.1007/BF00165134

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  36 in total

Review 1.  The mode of coupling of adenylate cyclase to hormone receptors and its modulation by GTP.

Authors:  A Levitzki
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

2.  Slowly reversible binding of catecholamine to a nucleotide-sensitive state of the beta-adrenergic receptor.

Authors:  L T Williams; R J Lefkowitz
Journal:  J Biol Chem       Date:  1977-10-25       Impact factor: 5.157

3.  Tentative identification of beta-adrenoreceptor subunts.

Authors:  D Atlas; A Levitzki
Journal:  Nature       Date:  1978-03-23       Impact factor: 49.962

4.  Magnesium dependence of agonist binding to adenylate cyclase-coupled hormone receptors.

Authors:  L T Williams; D Mullikin; R J Lefkowitz
Journal:  J Biol Chem       Date:  1978-05-10       Impact factor: 5.157

5.  Regulation of beta-adrenergic receptors by guanyl-5'-yl imidodiphosphate and other purine nucleotides.

Authors:  R J Lefkowitz; D Mullikin; M G Caron
Journal:  J Biol Chem       Date:  1976-08-10       Impact factor: 5.157

6.  N-glycosylation in expression and function of beta-adrenergic receptors.

Authors:  S T George; A E Ruoho; C C Malbon
Journal:  J Biol Chem       Date:  1986-12-15       Impact factor: 5.157

7.  The role of hormone receptors and GTP-regulatory proteins in membrane transduction.

Authors:  M Rodbell
Journal:  Nature       Date:  1980-03-06       Impact factor: 49.962

8.  High efficiency coupling between beta-adrenergic receptors and cardiac contractility: direct evidence for "spare" beta-adrenergic receptors.

Authors:  J C Venter
Journal:  Mol Pharmacol       Date:  1979-09       Impact factor: 4.436

9.  Agonist photoaffinity labeling of A1 adenosine receptors: persistent activation reveals spare receptors.

Authors:  M J Lohse; K N Klotz; U Schwabe
Journal:  Mol Pharmacol       Date:  1986-10       Impact factor: 4.436

10.  Interaction between beta-adrenergic receptors and guanine nucleotide sites in turkey erythrocyte membranes.

Authors:  G Vauquelin; S Bottari; C Andre; B Jacobsson; A D Strosberg
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

View more
  6 in total

1.  Photocytotoxicity of the fluorescent nonsteroidal androgen receptor ligand TDPQ.

Authors:  Piotr J Bilski; Boris Risek; Colin F Chignell; William T Schrader
Journal:  Photochem Photobiol       Date:  2009-05-28       Impact factor: 3.421

Review 2.  β(2) -adrenoceptor agonists: current and future direction.

Authors:  Mario Cazzola; Luigino Calzetta; Maria Gabriella Matera
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

3.  Persistent activation by and receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1 MF-2 cells and in guinea pig heart.

Authors:  J Zhang; L Belardinelli; K A Jacobson; D H Otero; S P Baker
Journal:  Mol Pharmacol       Date:  1997-09       Impact factor: 4.436

Review 4.  ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?

Authors:  Maria Gabriella Matera; Mario Cazzola
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Sigma binding in a human neuroblastoma cell line.

Authors:  J Ryan-Moro; C C Chien; K M Standifer; G W Pasternak
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

6.  Desensitization of alpha 2A-adrenoceptor signalling by modest levels of adrenaline is facilitated by beta 2-adrenoceptor-dependent GRK3 up-regulation.

Authors:  Tasneem Bawa; Ghazi F Altememi; Douglas C Eikenburg; Kelly M Standifer
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.